ALERT: ANTI-COMPETITIVE PRACTICE - HORIZONTAL ANTI-COMPETITIVE PRACTICE - VERTICAL ANTI-COMPETITIVE PRACTICE - DISTRIBUTION - REFUSAL TO SELL - LACK OF EVIDENCE

Horizontal and vertical anti-competitive practices: The French Competition Authority rejects a complaint regarding the distribution of non-reimbursable drugs (Pyxis Pharma / Sagitta Pharma)

Le 28 janvier 2016, l'Autorité de la concurrence a rendu publique la décision n° 16-D-01 du 20 janvier 2016 relative à la partie des pratiques visées à l’article L. 420-1 du code de commerce mises en œuvre dans le secteur de la distribution du médicament non remboursable. L'Autorité y rejette la saisine

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Horizontal and vertical anti-competitive practices: The French Competition Authority rejects a complaint regarding the distribution of non-reimbursable drugs (Pyxis Pharma / Sagitta Pharma), 20 January 2016, Concurrences Review N° 2-2016, Art. N° 79575, www.concurrences.com

Visites 231

All reviews